5 Dividend Stocks to Buy and Hold for the Next 5 Years

The article reviews five dividend-paying companies and the operating choices and risks relevant to a five-year hold. Oil-Dri’s fiscal 2026 sales rose 2% to $493.8 million and net income rose 6% to a record $57 million; it raised its common dividend about 10%. Results are mixed elsewhere: Weis revenue increased 4.6% as net income fell 9.6%, J&J Snack Foods sales declined 3.2% while gross margin rose to 28.8% and adjusted EPS increased 14.3%, and Tootsie Roll sales fell about 1% with EPS down to $0.31 from $0.48; Universal revenue slipped about 2%.

Analysis

The useful distinction is not dividend longevity but reinvestment runway. ODC has the clearest potential demand tailwind, but private-label substitution makes pricing and customer mix more important than headline sales growth; confirm branded volume, realized pricing, and share-class economics before paying for the growth. UVV’s ingredients business may soften tobacco decline, but it does not remove the risk that shrinking leaf volumes leave the consolidated business with less scale and weaker earnings quality. The dividend record is not a valuation floor.

JJSF’s margin-over-volume strategy is credible only if savings persist after fuel and retailer slotting costs. Over the next 1–3 months, watch gross margin and organic volume together: margin improvement with accelerating volume losses would undermine the thesis. TR’s weak quarter may partly reflect shipment timing and concentrated spending, so the next seasonal period is a better test than extrapolating one quarter; persistent cost inflation or weak sell-through would make the earnings dip structural. WMK’s upgrades may defend competitiveness, but the key question is incremental return on capital, not project count; pharmacy pressure and regional competition limit the case for a growth premium.

There is no broad dividend-stock trade here: yield and streaks alone provide little catalyst, and valuation, payout coverage, and liquidity data are absent. A cautious relative-value expression is long ODC versus short UVV only if valuation and borrow are workable, sized for UVV’s secular decline risk and ODC’s private-label exposure. The consensus trap is treating long dividend histories as downside protection; distributions can persist while the underlying earnings base deteriorates.

Key Decisions for Investors

• Watchlist: consider a modest long ODC / short UVV relative-value pair only after checking current valuation, dividend coverage, share-class terms, and short-borrow cost. Reassess if ODC loses litter volume or pricing momentum, or if UVV’s ingredients profits offset tobacco contraction more convincingly than expected.
• JJSF: do not chase a margin-recovery narrative on one quarter. Track gross margin alongside volume, fuel expense, and slotting costs over the next 1–3 months; deteriorating volume without sustained margin gains falsifies the operating-improvement thesis.
• TR: treat the earnings weakness as unresolved rather than automatically transitory. Use the next seasonal results and evidence on input-cost pass-through and sell-through as the catalyst; persistent margin pressure argues against relying on the dividend history.
• WMK: no compelling directional trade on the supplied evidence. Monitor comparable sales, pharmacy profitability, and returns on store investment; sustained earnings erosion despite sales growth would weaken the defensive case.